Richard Kyle, MD
Orthopaedic Surgery · Minneapolis, MNNPI 1720186588
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $24,673 of the $25,907 with a category attached, or 95.2%. Encore Medical, LP accounts for 95.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $15,842 and has fallen 98.4% since, to $260 in 2024.
Across 18 payments — averaging $1439.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Encore Medical, LP$25K
- Exactech, Inc.$755
- Stryker$197
- Smith+Nephew$178
- Spineology Inc.$88
- Si-bone, Inc.$15
Across 10 payments — averaging $3.80 each. An ownership or investment interest held by the physician or an immediate family member.
- Spineology Inc.$38
- Activortho, Inc.$0
What the payments were for
- Royalty or licence$24,67395%
- Speaking & faculty fees$880%
- Travel & lodging$5242%
- Food & beverage$6212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Encore Medical, LP | 9 | $24,673 |
| Exactech, Inc. | 4 | $755 |
| Stryker | 2 | $197 |
| Smith+Nephew | 1 | $178 |
| Spineology Inc. | 1 | $88 |
| Si-bone, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,907 in reported general payments places this provider in the 80th percentile of 533 orthopaedic surgery providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 24 | $592 |
| Tamsulosin Hcl | 15 | $195 |
| Metformin Hcl ErMetformin Hcl | 12 | $194 |
| Losartan Potassium | 13 | $159 |
| Metoprolol Succinate | 13 | $158 |
| Celecoxib | 13 | $107 |
| Ibuprofen | 12 | $73 |
| Meloxicam | 17 | $30 |
| Cephalexin | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Minneapolis
- David PollyMinneapolis$3.3M
- Ensor TransfeldtMinneapolis$2.3M
- Manuel PintoMinneapolis$1.7M
- Joseph PerraMinneapolis$1.6M
- Timothy GarveyMinneapolis$1.6M
- Amir MehbodMinneapolis$1.3M
- David TemplemanMinneapolis$361K
- Patrick YoonMinneapolis$203K
- Christopher MartinMinneapolis$131K
- Elizabeth ArendtMinneapolis$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.